Clinical trials: Degenerative Disease
Noninflammatory Degenerative Joint Disease
Survivorship of Attune Primary Total Knee Prosthesis
This post-marketing investigation will evaluate the long term (up to 15 years) survivorship of the Attune Primary Knee Prosthesis in patients with non-inflammatory degenerative joint disease.
- Trial name
- NCT01754363
- Testing
- Attune Primary Total Knee Replacement
- Where
- 27 sites in United States, Australia and 10 more
- Volunteers
- 1,542 people
- Sponsor
- DePuy International
Degenerative Lumbar Spondylolisthesis
OP-1 Putty for Posterolateral Fusions
The trial was designed to demonstrate the comparability of the overall success rate in the OP-1 Putty treatment group to the autograft treatment group.
- Trial name
- NCT00677950
- Testing
- Spinal fusion
- Where
- 24 sites in United States, Canada
- Volunteers
- 336 people
- Sponsor
- Olympus Biotech Corporation
Age-related Macular Degeneration
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
This study is conducted in 3 stages. Stage 1 is an open-label, dose-escalation assessment of the safety of AGN-150998 administered as a single intravitreal injection to patients with advanced exudative Age-related Macular…
- Trial name
- NCT01397409
- Testing
- AGN-150998, ranibizumab
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Allergan
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
- Trial name
- NCT05146687
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 369,600 people
- Sponsor
- Novartis Pharmaceuticals
Degenerative Disc Disease, Degenerative Spondylolisthesis
Lumbar Interbody Implant Study
The objective of this study is to evaluate the safety and performance of NuVasive interbody implants when used during thoracic and/or lumbar spine surgery as measured by reported complications, radiographic outcomes, and…
- Conditions
- Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Scoliosis, Spinal Stenosis
- Trial name
- NCT04418830
- Where
- 16 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- NuVasive
Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl).
- Trial name
- NCT00999609
- Testing
- AAV2-hRPE65v2,voretigene neparvovec-rzyl
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Spark Therapeutics, Inc.
Degenerative Arthritis, Inflammation
The Effects of Elmore Oil on Patients With Osteoarthritis
The treatment of osteoarthritis, a disease that eventually affects the majority of the older population, involves the alleviation of symptoms such as pain and stiffness, and the reduction of inflammation.
- Trial name
- NCT01684371
- Testing
- Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)
- Where
- Philippines
- Volunteers
- 60 people
- Sponsor
- Elmore Oil Company Pty Ltd
Degenerative Disc Disease
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
The purpose of this study is to compare two doses of immunoselected, culture-expanded, nucleated, allogeneic adult MPCs when combined with hyaluronic acid to two control intradiscal injections in subjects with chronic low back…
- Trial name
- NCT01290367
- Testing
- Single Dose MPCs Injection, Single injection of saline solution, Single injection of hyaluronic acid
- Where
- 14 sites in United States, Australia
- Volunteers
- 100 people
- Sponsor
- Mesoblast, Ltd.
Age Related Macular Degeneration
Macula Evolution in Patients With AMD Taking Oral Food Supplementation
LT7082-001 is an open-label, single-arm pilot study. Patients with intermediate age-related macular degeneration (AMD) wil take T7082 during 12 months , an association of 4 food supplementations .
- Trial name
- NCT04778436
- Testing
- T7082
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Laboratoires Thea
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or…
- Trial name
- NCT00134667
- Testing
- Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Eyetech Pharmaceuticals
Spinocerebellar Degeneration
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.
- Trial name
- NCT01970111
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Degenerative Disc Disease, Chronic Low-back Pain
Safety Study for An Artificial Disc Nucleus Replacement to Treat Chronic Low Back Pain
This study will be a prospective, open-label, multi-center study that will collect safety data for the minimally invasive PerQdisc Nucleus Replacement Device deployed to reduce chronic low back pain.
- Trial name
- NCT04004156
- Testing
- PerQdisc® Nucleus Replacement Device.
- Where
- 4 sites in Belgium, Canada and 2 more
- Volunteers
- 9 people
- Sponsor
- Spinal Stabilization Technologies
Early Lumbar Disc Degeneration
A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration
Study to show the safety, tolerability and preliminary effectiveness of Intradiscal rhGDF-5 in subjects with early lumbar disc degeneration
- Trial name
- NCT01182337
- Testing
- Intradiscal rhGDF-5, Vehicle control
- Where
- 7 sites in South Korea
- Volunteers
- 31 people
- Sponsor
- DePuy Spine
Age Related Macular Degeneration
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
The FORESEE HOME is used in the recent years to detect Age-related Macular Degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT00884637
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Degenerative Disc Disease, Grade 1 Spondylolisthesis
Idys™ TLIF 3DTi Post Market Clinical Follow-up
The aim of this observational post-marketing study is to provide additional information on the safety and effectiveness of Idys™ TLIF 3DTi at up to 24 months post transforaminal lumbar fusion in usual surgical practice.
- Trial name
- NCT04584619
- Testing
- Spine fusion surgery with Clariance Idys TLIF 3DTi
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Clariance
Eye Diseases, Macular Degeneration
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with…
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT02543229
- Testing
- OPT-302, Lucentis™
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Opthea Limited
Retinitis Pigmentosa
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa
The purpose of this first-in-human study is to explore the maximum tolerated dose (MTD) of CPK850 as determined by the single ascending dose ranging portion of the study.
- Trial name
- NCT03374657
- Testing
- CPK850
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Lower Back Pain, Degenerative Disc Disease (DDD)
Luna Interbody System for Fusion Trial
The purpose of this trial is to evaluate the performance, safety and effectiveness of the Luna system for the treatment of degenerative disc disease.
- Trial name
- LIFT (NCT01551901)
- Testing
- Spinal fusion
- Where
- 5 sites in Belgium, Germany
- Volunteers
- 100 people
- Sponsor
- Benvenue Medical, Inc.
Corneal Ectasia, Keratoconus
Safety and Effectiveness of the PXL-Platinum 330 System
To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.
- Conditions
- Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
- Trial name
- NCT04401865
- Testing
- PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Colorado Eye Consultants/Cornea Consultants of Colorado
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.